8011 related articles for article (PubMed ID: 2456315)
1. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi.
Paul E; Cochran AJ; Wen DR
J Cutan Pathol; 1988 Jun; 15(3):161-5. PubMed ID: 2456315
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits.
Cho KH; Hashimoto K; Taniguchi Y; Pietruk T; Zarbo RJ; An T
Cancer; 1990 Aug; 66(4):765-71. PubMed ID: 2201426
[TBL] [Abstract][Full Text] [Related]
3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
4. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
6. Growth dynamics of acquired melanocytic nevi. Higher reactivity of proliferating cell nuclear antigen in junctional and compound nevi than intradermal nevi.
Tokuda Y; Saida T; Mukai K; Takasaki Y
J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):220-4. PubMed ID: 7913717
[TBL] [Abstract][Full Text] [Related]
7. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
8. Detection of S-100 protein as an aid to the identification of melanocytic tumors.
Cochran AJ; Wen DR; Herschman HR; Gaynor RB
Int J Cancer; 1982 Sep; 30(3):295-7. PubMed ID: 6752046
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
10. Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections.
Duray PH; Palazzo J; Gown AM; Ohuchi N
Cancer; 1988 Jun; 61(12):2460-8. PubMed ID: 3365669
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical evaluation of uveal melanocytic tumors. Expression of HMB-45, S-100 protein, and neuron-specific enolase.
Burnier MN; McLean IW; Gamel JW
Cancer; 1991 Aug; 68(4):809-14. PubMed ID: 1855181
[TBL] [Abstract][Full Text] [Related]
12. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
13. Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors.
Thompson JJ; Herlyn MF; Elder DE; Clark WH; Steplewski Z; Koprowski H
Am J Pathol; 1982 Jun; 107(3):357-61. PubMed ID: 6177248
[TBL] [Abstract][Full Text] [Related]
14. Comparison of five antimelanoma antibodies for identification of melanocytic cells on tissue sections in routine dermatopathology.
Thomson W; MacKie RM
J Am Acad Dermatol; 1989 Dec; 21(6):1280-4. PubMed ID: 2685063
[TBL] [Abstract][Full Text] [Related]
15. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
16. Immunohistologic evidence for the malignant potential of congenital melanocytic nevi.
Steijlen PM; Hamm H; van Erp EJ; Johnson JP; Ruiter DJ; Bröcker EB
J Invest Dermatol; 1989 Mar; 92(3):366-70. PubMed ID: 2645372
[TBL] [Abstract][Full Text] [Related]
17. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
Kornstein MJ; Brooks JS; Elder DE
Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
[TBL] [Abstract][Full Text] [Related]
18. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
19. A study of the so-called neurotization of nevi.
Van Paesschen MA; Goovaerts G; Buyssens N
Am J Dermatopathol; 1990 Jun; 12(3):242-8. PubMed ID: 1693816
[TBL] [Abstract][Full Text] [Related]
20. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.
Skelton HG; Smith KJ; Barrett TL; Lupton GP; Graham JH
Am J Dermatopathol; 1991 Dec; 13(6):543-50. PubMed ID: 1725245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
